The Central Commission for Discipline Inspection issued a document to strictly investigate medical corruption

Recently, the Central Commission for Discipline Inspection issued a document naming medical corruption, hospital leaders were investigated, and 12 bribery personnel were detained

1.

According to Cyberlan, 12 suspects of bribery were detained and involved two hospital leaders, namely Yuan Mou, Secretary of the Party Committee of Kunming Medical University, and Ma Moumou, former vice president of Fuwai Cardiovascular Hospital in Yunnan Province.

On April 1, according to a public notification by the Yunnan Provincial Commission for Discipline Inspection, Zhu Moumou, the legal representative of Yunnan Branch of Sichuan Kemao Construction Engineering Co.

It is understood that on February 21 this year, the Yunnan Provincial Commission for Discipline Inspection said that Yuan Mou, Secretary of the Party Committee of Kunming Medical University, accepted disciplinary review and supervision and investigation.

The article pointed out that since this year, the Yunnan Provincial Commission for Discipline Inspection has successively taken liens in accordance with the law on three batches of 12 persons suspected of bribery in the medical field.

After investigation, Cyberlan found that Ma Moumou, the former vice president of Fuwai Cardiovascular Hospital in Yunnan Province, seriously violated laws and disciplines, and involved 8 persons suspected of bribery, all of which were detained.

Including Mr.

It can be seen that among the 12 persons suspected of bribery involved many middle-level and senior leaders of pharmaceutical companies.

2.

With the increasing efforts to correct corruption and work style problems in the fields of education, medical care, food and drug safety in Yunnan, Ma Moumou, former vice president of Fuwai Cardiovascular Hospital in Yunnan Province, voluntarily surrendered to the Provincial Commission for Discipline Inspection and Supervision, and accepted disciplinary review and supervision survey.

After investigation, it was found that Ma Linkun's violation of discipline and law involved dozens of suppliers of medicines, medical devices and consumables.

In addition to the hospital leaders mentioned above, on March 30, 2021, the National Supervision Commission of the Central Commission for Discipline Inspection issued a notice stating that according to the news from the Yunnan Provincial Commission for Discipline Inspection: Wenshan Zhuang and Miao Autonomous Prefecture CPPCC retains deputy department-level treatment cadres (Wenshan Prefecture People’s Hospital Former President) Lu Mou is suspected of serious violations of the law, has voluntarily surrendered, and is currently under supervision and investigation.

3.

On January 25, 2021, the Communiqué of the Fifth Plenary Session of the 19th Central Commission for Discipline Inspection of the Communist Party of China published on the 01th page of the People’s Daily made it clear that the Central Discipline Inspection Commission’s 2021 tasks include: continuous rectification of the masses Corruption and unhealthy trends around us continue to correct corruption and work style problems in education and medical care, food and drug safety, law enforcement and justice.

In addition, it is worth noting that the Central Commission for Discipline Inspection mentioned in the article "Being on the "Blacklist" and Making Bribery Steps Difficult" 4 days ago-In the past, one of the reasons why some bribers were bold and reckless was that the cost of illegality was too low.
.

To prevent the phenomenon that only punishes the bribes but allows the bribers to go unpunished, it is necessary to adopt system constraints to keep the bribers out of the door-the work report of the Fifth Plenary Session of the 19th Central Commission for Discipline Inspection pointed out that exploring the implementation of a "blacklist" system for bribers , Strictly investigate and deal with numerous acts of bribery and huge amount of bribery.

Reputation is the foundation of a company's survival.
The inclusion of bribery subjects into the "blacklist" and public exposure and joint punishment will help build a social credit system, increase the cost of bribery, and make it difficult for bribers to do so.

In addition, because one briber often corresponds to multiple bribers, the "blacklist" is also conducive to follow-through investigations of bribery.
Once the case is found to be associated with a certain briber in the "blacklist", it can be further investigated.

On the one hand, the work of the Central Commission for Discipline Inspection in 2021 has clearly stated that it will strengthen the correction of corruption and work style issues in the medical and pharmaceutical fields; on the other hand, the work report of the Fifth Plenary Session of the 19th Central Commission for Discipline Inspection pointed out that bribery space should be reduced and bribery should be investigated together.

From these signals, it can be seen that pharmaceutical companies, as the bribers of drug kickbacks and pharmaceutical corruption in the pharmaceutical field, will usher in more stringent rectification efforts.

4.
Multi-party rectification, medical corruption is facing high pressure

In addition to the bribery blacklist system of the Central Commission for Discipline Inspection, the medical recruitment credit evaluation system established by the National Medical Insurance Bureau also incorporates rebates or other improper benefits in the purchase and sale of medicines into the credit evaluation system.

According to the regulations of the National Medical Insurance Administration, pharmaceutical companies do not submit credit commitments to provincial recruitment platforms and will face the consequences of product withdrawal from June 1st.
After submitting credit commitments, pharmaceutical companies will continue to increase their level of untrustworthiness.
, May also face the punishment of being restricted or suspended for all medicines and medical consumables, bidding or distribution qualifications.

It is worth noting that this system is clear that the pharmaceutical company as an independent legal person submits a written commitment to bear the responsibility for the dishonesty of the employees (including the employment relationship) or the distribution company with an agency relationship in the process of selling its own drugs or medical consumables.

On December 25, 2020, the National Medical Insurance Administration issued the "Notice on Accelerating the Implementation of the Medical Price and Recruitment Credit Evaluation System" and further required the medical recruitment credit evaluation system to make substantive progress as soon as possible.
Centralized procurement agencies in all provinces should follow the principle of territoriality.
Pay close attention to the judgment documents and administrative punishment decisions published by the local courts, taxation, market supervision and other departments, and obtain substantive governance results in credit rating and tiered disposal as soon as possible.

According to a review, as many as a dozen provinces and cities have recently issued a list of pharmaceutical companies that have not submitted credit undertakings, urging pharmaceutical companies to submit credit undertakings as soon as possible, and as many as thousands of pharmaceutical companies have been named.

In addition, corruption and work style issues in the medical and pharmaceutical fields are also the focus of inspections of large hospitals carried out by the National Health Commission-according to the "Notice on Printing and Distributing the Inspection Work Plan for Large Hospitals (2019-2022)" issued by the National Health Commission 》, the commission of drug prescriptions, the receipt of rebates, and the private procurement of drugs and consumables are all within the scope of inspection.

The National Health Commission requires that in principle, the number of inspection days for each hospital should be no less than 7 days, using self-inspection combined with on-site inspections, starting in November 2019, and completing this round of inspections before the end of June 2022—that is, Inspections in large hospitals are still in progress.

Generally speaking, the correction of corruption and work style issues in the pharmaceutical and medical fields is still in progress, and the pressure on pharmaceutical companies as the nominal bribery subjects is further increasing.